{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:24:56Z","timestamp":1769696696393,"version":"3.49.0"},"reference-count":27,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Far Eastern Memorial Hospital","award":["FEMH-YZU-2021-008"],"award-info":[{"award-number":["FEMH-YZU-2021-008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Our study compared the visual and anatomical outcomes of polypoidal choroidal vasculopathy (PCV) patients receiving intravitreal aflibercept (IVA) with or without photodynamic therapy (PDT) over 12 months. Materials and Methods: This retrospective study was performed for 60 eyes from 60 patients with treatment-na\u00efve PCV. Thirty eyes were treated using IVA monotherapy (IVA group), and thirty eyes were treated using a combination of IVA with PDT (IVA\/PDT group). The baseline characteristics, treatment outcomes, and retreatment rates were compared between the two groups over a one-year follow-up period. Results: The best-corrected visual acuity (BCVA) was found to have improved significantly in the IVA\/PDT group at every 3-month visit. However, no significant BCVA improvement was observed in the IVA group. A significantly lower retreatment rate and higher dry macula rate were found in the IVA\/PDT group than that in the IVA group. In the entire population of the study, a better baseline vision and younger age were associated with better final visual outcomes. Retreatment was associated with poor baseline BCVA and IVA monotherapy. Conclusions: The combination of IVA and PDT may offer superior visual improvement and a higher dry macula rate compared to IVA monotherapy in the treatment of PCV patients while requiring fewer retreatments over 12 months.<\/jats:p>","DOI":"10.3390\/medicina60081311","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T03:46:36Z","timestamp":1723607196000},"page":"1311","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of One-Year Outcome of Intravitreal Aflibercept with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy"],"prefix":"10.3390","volume":"60","author":[{"given":"Hsin-Yu","family":"Weng","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 100, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0294-4203","authenticated-orcid":false,"given":"Ling-Uei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Lun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan"},{"name":"Department of Electrical Engineering, Yuan Ze University, Taoyuan City 320, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ting","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 100, Taiwan"},{"name":"Department of Medicine, National Yang Ming University, Taipei City 112, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yao","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 100, Taiwan"},{"name":"Department of Electrical Engineering, Yuan Ze University, Taoyuan City 320, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Ray","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 100, Taiwan"},{"name":"Department of Electrical Engineering, Yuan Ze University, Taoyuan City 320, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Ju","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 100, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3157-3613","authenticated-orcid":false,"given":"Jia-Kang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan"},{"name":"Department of Medicine, National Taiwan University, Taipei City 100, Taiwan"},{"name":"Department of Electrical Engineering, Yuan Ze University, Taoyuan City 320, Taiwan"},{"name":"Department of Medicine, National Yang Ming University, Taipei City 112, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"ref_1","first-page":"359","article-title":"Polypoidal choroidal vasculopathy: An update on therapeutic approaches","volume":"8","author":"Wong","year":"2013","journal-title":"J. Ophthalmic. Vis. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","article-title":"Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease?","volume":"29","author":"Laude","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: Definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","article-title":"Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics","volume":"121","author":"Sho","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1167\/iovs.10-5554","article-title":"Cfh and arms2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation","volume":"51","author":"Hayashi","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","article-title":"Clinical characteristics of exudative age-related macular degeneration in japanese patients","volume":"144","author":"Maruko","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.survophthal.2003.10.007","article-title":"Polypoidal choroidal vasculopathy","volume":"49","author":"Ciardella","year":"2004","journal-title":"Surv. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1097\/IAE.0b013e31820d3f28","article-title":"Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a japanese population over 1 year of follow-up","volume":"31","author":"Bessho","year":"2011","journal-title":"Retina"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","article-title":"Polypoidal choroidal vasculopathy: Natural history","volume":"133","author":"Uyama","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"Everest study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The everest ii randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"Vegf-trap: A vegf blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","article-title":"Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy","volume":"165","author":"Cho","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00417-016-3500-1","article-title":"One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy","volume":"255","author":"Matsumiya","year":"2017","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol.\/Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Treatment of age-related macular degeneration with photodynamic therapy (tap) study group (1999). Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials\u2013tap report. Arch. Ophthalmol., 117, 1329\u20131345.","DOI":"10.1001\/archopht.117.10.1329"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00006982-200502000-00002","article-title":"Guidelines for using verteporfin (visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: Update","volume":"25","author":"Participants","year":"2005","journal-title":"Retina"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Takayama, K., Kaneko, H., Kataoka, K., Hattori, K., Ra, E., Tsunekawa, T., Fukukita, H., Haga, F., Ito, Y., and Terasaki, H. (2017). Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176100"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00417-016-3467-y","article-title":"Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"255","author":"Kikushima","year":"2017","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol.\/Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol."},{"key":"ref_19","first-page":"80","article-title":"Efficacy and safety of intravitreal aflibercept treat and extend for polypoidal choroidal vasculopathy in the atlantic study: A randomized clinical trial. Ophthalmologica. Journal international d\u2019ophtalmologie","volume":"245","author":"Silva","year":"2022","journal-title":"Int. J. Ophthalmol.\/Z. Fur Augenheilkd."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ajo.2013.11.015","article-title":"Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: Long-term visual outcome","volume":"157","author":"Kang","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","article-title":"Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month laptop study results","volume":"156","author":"Oishi","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ophtha.2013.12.037","article-title":"Laptop study: A 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy","volume":"121","author":"Oishi","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s10384-020-00805-5","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the japanese subgroup of the planet study","volume":"65","author":"Ogura","year":"2021","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s00417-022-05724-4","article-title":"Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a european cohort","volume":"260","author":"Liu","year":"2022","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol.\/Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wataru, K., Sugiyama, A., Yoneyama, S., Matsubara, M., Fukuda, Y., Parikh, R., and Sakurada, Y. (2020). Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229231"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lee, J., Kim, K., Kim, E.S., Yu, S.Y., and Kang, M.S. (2023). Seven-year outcomes of combined treatment of anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy; according to polypoidal lesion regression. BMC Ophthalmol., 23.","DOI":"10.1186\/s12886-023-03264-x"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/8\/1311\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:36:15Z","timestamp":1760110575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/8\/1311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["medicina60081311"],"URL":"https:\/\/doi.org\/10.3390\/medicina60081311","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}